ClinicalTrialsFinder
RecruitingNCT04340986

Cohort of Patients With Hepatocellular Carcinoma or Cholangiocarcinoma

Cohort Study of Patients With Primary Hepatocellular Carcinoma or Cholangiocarcinoma

Sponsor

Assistance Publique - Hôpitaux de Paris

Enrollment

1,250 participants

Start Date

Sep 2, 2020

Study Type

OBSERVATIONAL

Conditions

CholangiocarcinomaHepatocellular Carcinoma

Summary

The main objective is to describe the evolution of patients treated for a primary malignant hepatobiliary tumor (hepatocellular carcinoma or cholangiocarcinoma) over the long course.

Eligibility

Min Age: 18 Years

Inclusion Criteria7

  • Age ≥ 18 years olds
  • Medical care in Nephrology department since 2015
  • Cholangiocarcinoma:
  • \- Histologically and cytologically documented cholangiocarcinoma, regardless of the stage of the disease
  • Hepatocellular carcinoma:
  • Hepatocellular carcinoma at any stage of the disease, presenting the diagnostic criteria according to the diagnostic criteria of Barcelona : Tumor of more than 1 cm, developed on cirrhosis liver with arterial phase hyperenhancement and washout in the portal venous or delayed phases on CT and MRI
  • Hepatocellular histologically documented

Exclusion Criteria1

  • \- Lack of patient non-opposition

Locations(1)

Serviec hépatologie-Hôpital Saint Antoine

Paris, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04340986

Related Trials

Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus Pembrolizumab

NCT066480571 location

Prevention of Variceal Rebleeding by EUS-guided vs Conventional Endoscopic Therapy in Hepatocellular Carcinoma Patients

NCT056298451 location

Prospective Clinical Validation of Next Generation Sequencing (NGS) and Patient-Derived Tumor Organoids (PDO) Guided Therapy in Patients With Advanced/ Inoperable Solid Tumors

NCT060775911 location

Identification of Innovative Biomarkers to Predict Outcomes in Hepatocellular Carcinoma Treated With Tremelimumab and Durvalumab

NCT0679611410 locations

Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients

NCT054683592 locations